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The 4th European Society of Pharmacogenomics and Personalised Therapy (ESPT) biennial 
conference was organized in collaboration with the Italian Society of Personalized Medicine 
(SIMeP) and was held at Benedictine Monastery of San Nicolò l'Arena in Catania, Sicily (IT) on 
4-7 October 2017. The congress addressed the research progress and clinical implementation in 
pharmacogenomics and personalised medicine. The 4th ESPT congress brought together leading 
international scientists and healthcare professionals actively working in the fields of 
pharmacogenomics and personalised therapy. Altogether, 25 speakers in 15 session 
comprehensively covered broad spectrum of pharmacogenetics and pharmacogenomics research, 
clinical applications in different clinical disciplines attended by 270 delegates. 
 







The 4th Conference of the European Society for Pharmacogenomics and Personalised 
Therapy (ESPT) was held in collaboration with the Italian Society of Personalized Medicine 
(SIMeP), under the auspices of European Federation of Clinical Chemistry and Laboratory 
Medicine (EFLM), Federation of Clinical Chemistry and Laboratory Medicine (IFCC), SIF 
(Societa Italiana di Farmacologia) on 4-7 October 2017 in Catania, Italy. The historical 
Benedictine Monastery of San Nicolò l'Arena, served as congress venue. 
After successful events in the previous years (Budapest 2015, Lisbon 2013, Bled 2011), 
the Catania congress again brought together leading international scientists, healthcare 
professionals and stakeholders of pharmacogenomics and personalised therapy, striving to 
enhance the scientific interaction and facilitate diagnostic implementation of pharmacogenomics.  
The mission of ESPT is to contribute to safer and more efficient use of drug therapy for every 






The Conference was opened by Prof. Urs Meyer (CH), BioZentrum University Basel, giving an 
overview on seven decades of therapeutic lessons for human individuality, showing where 
pharmacogenetics and pharmacogenomics have started, and showing the current status as well as 
the future perspectives, as addressed in challenges and opportunities, and lessons to be learned 
from history. The opening session was extended by an excellent lecture of Prof. Ann Daly (UK), 
Newcastle University, Newcastle upon Tyne, focusing on the genetics of drug induced liver injury, 
showing that idiosyncratic drug-induced liver injury (DILI) is rare (1:10,000-100,000) but can 
cause serious toxicity, with 5-10% of cases to develop potentially fatal liver failure, requiring 
transplantation. For flucloxacillin, a DILI GWAS study identified a strong correlation with HLA-
B*57:01, with the HLA-B*57:03 as an alternative risk factor. HLA-A*3301 was significantly 
associated with DILI for a.o. terbinafine, ticlopidine (Omnibus GWAS). The role of PTPN22 
associated with DILI was described. 
 
Prof. Adrian Llerena (ESP) indicated that pharmacogenetics and personalized medicine are 
expected to be helpful in clinical decision making for depression in general, and particularly for 
suicide. The relationship between drug metabolizing genes and suicide can be due to different 
mechanisms. Prof. Llerena indicated that there does not appear to be clinical trials directly 
exploring suicide risk, since available information is mostly based on indirect analyses of suicidal 
events as adverse drug reactions (ADRs) during clinical trials on antidepressant drugs. 
Pharmacogenes could be helpful to explain suicidal events in relation to the lack of efficacy for a 
prescribed/standardized antidepressant drugs treatment in an individual vulnerable to suicide. 
  
Prof. Ewan Pearson (UK) opened the session on cardiovascular and antidiabetic drugs stating 
that pharmacogenetics should be part of mainstream clinical care. He outlined key areas where 
genetic variants altered drug response in type 2 diabetes, such as CYP2C9 for sulphonylureas and 
SLC2A2 for metformin response. Prof. Alfredo Ferro (IT) gave an introduction to computational 
pathway analysis and presented several examples how this can be applied in pharmacogenomics. 
Dr. Chiara di Resta (IT) presented an overview of the recent developments and challenges of 
sequencing in cardiopathies. The complexities of the disease make variant interpretation 
challenging and whilst sequencing offers the ability to evaluate multiple genes simultaneously, it 
does create challenges with deciding on pathogenicity and when to report variants of uncertain 
significance. Mutations can be associated with different clinical phenotypes (e.g. both conduction 
and structural disorders); half of patients have no variants whereas 20% have multiple variants in 
multiple genes.  Prof. Vangelis G. Manolopoulos (GR) presented a lecture on the current state 
regarding pharmacogenomics for cardiovascular drugs, showing a prominent role for genetic 
variation for anticoagulants, clopidogrel, beta blockers, cholesteryl ester transfer protein (CETP) 
inhibitors and statins. Open issues and questions blocking wide adaptation of pharmacogenomic 
testing into routine cardiovascular clinical practice were addressed. The speaker concluded that 
cardiovascular drug pharmacogenomics and therapy personalization is neither a reality nor a hype, 
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but rather an uphill long-distance track we must strive to continue successfully for the benefit of 
our patients and society.  
 
Prof. Laure Elens (BE) presented pharmacogenomics for guiding immunosuppression in solid 
organ transplantation. The presentation began with a review of tacrolimus for liver and kidney 
transplantation demonstrating that the drug is highly variable in terms of pharmacokinetics and 
pharmacodynamics. A case of two patients with highly different pharmacokinetics was presented, 
highlighting the importance of CYP3A5, CYP3A4 and ABCB1 in tacrolimus metabolism. In the 
second part of the talk, the pharmacogenomics of cyclosporine, mycophenolate mofetil (MMF) 
and inosine monophosphate dehydrogenase (IMPDH) was discussed. Prof. Sofia Siest (FR) 
addressed VEGF as a potential biomarker for systems medicine. She demonstrated that four SNPs 
in VEGF gene can explain 50% of heritable variability in gene expression, also showing functional 
implications of these variations. Lecture concluded by presentation of current activities and future 
plans within the VEGF consortium. Dr. Maja Matic (NL) presented clinical studies on 
pharmacogenomics and pain. Main drugs used for controlling the pain are opioids and their mode 
of action with candidate gene approach was extensively reviewed in the beginning of the lecture. 
Out of ten selected genes investigated for association with codeine, three were significantly 
associated with efficacy and adverse side effects: CYP2D6, OPRM1 and COMT. Next results of 
studies on cardiac surgery and cancer patients were presented demonstrating OPRM1 and COMT 
are associated with higher dose requirements for analgesia. In children, tramadol was investigated 
in conjunction with CYP2D6, OPRM1 and OCT-1 transporter. The presentation was concluded by 
a discussion on the importance of variant and gene interaction for explanation of associations with 
drug efficacy and toxicity. 
 
The Italian Society of Personalized Medicine (SIMeP) session was opened by SIMeP President 
Prof. Paolo Marchetti, from Sapienza University of Rome, who gave an overview on the state of 
the art and the perspective of personalized medicine in oncology. He highlighted that “Imprecision 
medicine” leads to drastically high rate of inefficacy or toxicity during treatment with main drug 
classes. Prof. Marchetti continued stressing the importance to address the problem of patient’s 
adherence to the therapy. Patient’s non-adherence is a main source of inefficacy and increasing 
quality, efficacy and tolerability of pharmacological treatment by targeted therapy prescription 
may represent the key to increase patient’s compliance. Prof. Marchetti presented data showing 
that a preemptive biochemical functional assay performed on peripheral blood mononuclear cells 
is able to predict severe toxicity and is probably linked to clinical outcome, and has improved 
predictive performance compared to currently used pharmacogenetic testing. Prof. Maurizio 
Simmaco (IT) presented the organizational model of the Personalized Medicine service at the 
Sant’Andrea Hospital of Rome, which is based on integration of genotype and phenotype 
characterization. Genome based prediction of drug response is flanked by phenotypic evaluation 
using therapeutic drug monitoring, biochemical functional assays and metabolomics. Prof. 
Simmaco showed the high potential of liquid chromatography coupled with tandem mass 
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spectrometry to develop rapid, robust, effective and low cost analytical assay for phenotype 
characterization. He presented examples for (1) evaluation of intestinal permeability (2) detection 
of neurosteroids and (3) studying metabolites of the kynurenine pathway. Prof. Monica Miozzo 
(IT) presented the concomitant detection of chromosome 1p/19q codeletion and IDH1, IDH2 and 
TERT mutation status by Mass Array approach in glioma. The talk addressed the recently revised 
glioma diagnosis WHO guidelines which integrates molecular parameters and demonstrated the 
development of a reliable, accurate, rapid, and cost-effective MassARRAY (MS)-based test that 
can identify 1p/19q codeletion using quantitative SNP genotyping and, simultaneously, 
characterize hotspot mutations in the IDH1, IDH2, and TERT genes in tumor DNA. Furthermore, 
this MS approach could be similarly exploited in evaluation of loss of heterozygosity (LOH) in 
other tumors for clinical and/or research importance (1). Prof. Marianna Nuti (IT) explained that 
immune cells can shape the outcome of various anticancer therapies. Accumulating data suggest 
that antitumor activity of conventional cancer therapy results in part from its ability to harness the 
innate and adaptive immune systems by inducing immunologically active tumor cell death. Pre-
existing immunity against tumor cells is the factor that influences the response to standard and 
target therapies. Immune checkpoint inhibitors (ICI) have recently been introduced as novel 
therapeutic strategy in the treatment of cancer. Pre-existing natural or induced anti-tumor 
immunity is one of the variables that has been associated with increased response and the 
concomitant elimination of immune-suppressive cells are also dominant mechanisms of enhanced 
antitumor activity. Immunoncology is entering the field of precision medicine and a number of 
emerging biomarkers are now been validated in the different clinical settings.   
 
Dr. Patricia Curtis (CH) opened the Pharmacogenomics in Oncology session with DNA repair 
genes associated with chemotherapy and stem cell bone marrow transplantation. Acute graft versus 
host disease (aGvHD) is one of the main reasons of mortality and conditioning regimen as 
important factor for success of hematopoietic stem cell transplantation (HSCT). Phases of aGvHD 
were described by focusing on DNA damaging mechanisms of busulfan and latter release of 
damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) by damaged cells and their activation of immune system. MGMT was a gene that 
exhibited significant association with aGvHD. Prof. Thomas Muerdter (GE) presented 
pharmacogenomics of tamoxifen. The intracellular metabolism through CYP2D6, the generation 
of endoxifen and the implication for clinical practice and current pharmacogenomics guidelines 
for tamoxifen administration were addressed. LOH was demonstrated to be an important factor 
determining tamoxifen treatment effect. Three possible options for translating current knowledge 
into the clinical practice were discussed: dose escalation, high dose endoxifen treatment or 
supplementation of tamoxifen with low doses of endoxifen. Dr. Linda Henricks (NL) showed 
the clinical value of DPYD-guided dosing of fluoropyrimidines. Results of a prospective clinical 
trial on 2,035 patients demonstrated a significant risk of toxicity for slow metabolizers. This 
toxicity risk could be reduced from 73% to 30% in case of genotype-based dose adjustment. In 
addition, appropriate plasma concentrations were achieved significantly faster when using 
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pretreatment genotyping leading to significantly economic benefits by improving patient’s safety. 
Lecture was concluded by presentation of new project focused on implementation of new 
screening tests for dihydropyrimidine dehydrogenase (DPD) pretreatment phenotyping.  
 
Prof Romano Danesi (IT) highlighted the use and clinical utility of cell free DNA analysis using 
digital droplet PCR (ddPCR) to detect the EGFR T790M mutation in lung cancer patients. 
Detection of this mutation will drive a change of therapy towards the use of osimertinib, because 
of associated tyrosine kinase inhibitors (TKIs) resistance. Dr. Marzia del Re (IT), continued on 
the use of exosomal derived AR-V7 for the detection of prostate cancer resistance, again using 
ddPCR. This approach showed a better discrimination between AR-V7 positive and AR-V7 
negative patients compared with the paper of Antonarakis, who showed a progression free survival 
of 6.2 months for Ar-V7 negative patients as determined using circulating tumor cells (CTCs), 
against a progression free survival of 20 months using AR-V7 detection through exosomes. This 
suggested that the AR-V7 negative patients in the Antonarakis study may have been missed due 
to the lower sensitivity of CTCs versus exosomal AR-V7 analysis. Prof Winand Dinjens (NL) 
presented Next Gen Sequencing (NGS) with Unique Molecular Identifiers (UMIs) for the sensitive 
detection of mutations in EGFR in cell free DNA from lung cancer patients. By using UMIs, a 
very high sensitivity could be obtained, comparable to the digital droplet PCR approach. The 
advantage of NGS being that multiple mutations can be monitored than just T790M, Exon19del, 
L858R or C797S, as done with ddPCR. 
 
Helen Gautschi (SA), from DNAlysis Biotechnology, presented the practical application of 
nutrigenomics and nutrigenetics. Mrs. Gautschi analyzed how dietary improvement (vitamins B12 
and B6, folic acid and omega-3 fatty acids) may provide an efficacious and accessible treatment 
strategy for the management of highly prevalent mental disorder, including depression. She 
showed beneficial effect of adjunctive l-methylfolate 15 mg among inadequate responders to 
selective serotonin reuptake inhibitors (SSRIs) in depressed patients who were stratified by 
biomarker associated with inflammation or metabolism levels and genomic markers associated 
with l-methylfolate synthesis and metabolism. The presentation continued with outline of research 
studies that explored SNPs that alter IL-1 activity (IL-1A 4845 G>T & -889 C>T, IL-1B 3954 C>T 
& -511 A>G, and IL-1RN 2018 C>T) and the course of certain chronic diseases, followed by 
presenting how specifically formulated botanical mixture targeting IL-1 production and response 
was able to significantly reduce IL-1 gene expression and C-reactive protein (CRP) in healthy 
individuals carrying gene variations associated with IL-1 overexpression. Carlos Malpica (USA), 
from Metabolon Inc. gave a lecture about adding precision metabolomics applied to personalized 
medicine. In the introduction, he explained that metabolomics improves understanding of health 
and the influences of diet, drug treatment, genes and lifestyle. Dr Malpica presented the main 
principle of the patented technology that automatically compares the generated data against an 
extensive chemical library to isolate relevant metabolites in minutes, giving accurate, and 
reproducible result. In the second part of the talk Meta IMD™ - comprehensive analysis of 
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hundreds of metabolites associated with a wide range of inherited metabolic disorders using 
Metabolon’s proprietary technology and informatics was presented. It simultaneously surveys 
individual metabolites and pathways across amino acids, carbohydrates, organic acids, fatty acids, 
neurotransmitters, nucleotides and bile acids to detect biochemical abnormalities associated with 
a wide range of Inherited metabolic disorders, and may also spot disorders for which there is 
presently no biochemical testing available. The metabolic signature consistent with early signs of 
disease conditions and drug effects associated with efficacy and toxicity was explained. Lecture 
concluded by presentation of metabolomics as an effective approach to complement NGS for 
disease risk assessment, disease monitoring, and customized drug therapy in clinics. 
 
This year, aiming to provide an inspirational platform for young scientist, ESPT board introduced 
a new session focusing on young investigators. The ESPT Poster Committee selected the three 
best abstracts for oral presentation. Dr. Matthias Samwald (AT) from the Medical University of 
Vienna gave a lecture about establishing multi-lingual, multi-modal pharmacogenomic decision 
support. The Ubiquitous Pharmacogenomics (U-PGx) project is an international, multidisciplinary 
effort aiming to implement pharmacogenomics-guided drug dosing across seven European 
countries. Advantages of the developed system are safe use of patient data and adoption to local 
languages. Irene Dapia (ES), INGEMM Hospital Universitario La Paz in Madrid, presented on 
the implementation of pharmacogenetics (PGx) in the Spanish National Health System. She 
revealed that the most relevant barriers for the implementation of PGx in the clinical practice are 
low institutional promotion, lack of clinical guidelines and economical aspects. Therefore, they 
created a PGx Unit aiming to provide consultation and genotyping of 180 SNPs (PharmArray®). 
As an outcome, in the clinical recommendation both the predicted phenotype and the clinical 
information are individually integrated for each patient. Dr. Sylvie Quaranta (FR) explained the 
levels of evidence and recommendations developed at the French Network of Pharmacogenetics 
(RNPGx) aiming for pharmacogenetics-based personalized therapy in four major therapeutic 
domains. The RNPGx classification integrates the functional impact of genetic variations, the 
nature of the phenotype concerned, the clinical evidences available, and the existence of non-
genetic options for treatment personalization. Based on this, three levels of evidence were 
developed: (i) ‘essential’ in the case of unpredictable clinical phenotype of major importance by a 
non-genetic approach; (ii) ‘advisable’ in the case of intermediary phenotypes or for clinical 
phenotypes of major importance, but predictable by non-genetic methods; (iii) ‘possibly useful’ in 
case of intermediary phenotypes with less robust evidences but useful case-by-case. 
 
Prof. Ingolf Cascorbi (DE) opened the session on PGx on drug transporters talking about new 
SNPs and clinical applications of CYP3A4 genetic variants. He emphasised the clinical importance 
of CYP3A5*3 contributing to variability of drug response of tacrolimus. CYP3A4*22 significantly 
affected trough/dose concentration ratios, whereas variants in related genes such as NR1/2, POR 
or PPAR alpha have only minor impact. Hence, combination of CYP3A5*3 and CYP3A4*22 
explains best interindividual variability of tacrolimus pharmacokinetics. Of major clinical 
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importance are rare but functionally inactive specific SNPs creating a premature stop-codon like 
in CYP3A4*20 and CYP3A4*26.  It can be expected that wider application of NGS technologies 
will lead to the discovery of more rare variants contributing to the explanation of overall variability 
of CYP3A4 activity.  Dr. Charity Nofziger (AUT) talked about in depth analysis of CYP2D6. 
This locus is extremely complex containing variable number of structurally similar pseudogenes 
and accurate sequences cannot be obtained using standard NGS methods, but long read methods 
are required. In particular this laboratory has identified many novel CYP2D6/CYP2D7 hybrids. In 
her lecture she gave examples of the most complex gene arrangements and pinpointed the necessity 
of careful validation of the methods used for identification of the genetic variants. Dr. Jos 
Kleinjans (NL) talked about miRNAs as pharmacogenomic biomarkers for drug safety. He gave 
an overview of acetaminophen-induced miRNAs and their target mRNAs which were to a great 
extent related to immune response, and apoptosis/DNA damage. The miRNAs could be clustered 
in relation to type of liver injury. He concluded that these miRNAs could be examined as novel 
biomarkers for drug injury and disease. Prof. Magnus Ingelman-Sundberg (SWE) talked about 
sequencing rare variants as the next step in pharmacogenetics. He gave an overview about the 
current pharmacogenomic biomarkers and then presented a study where the CYP2C19 genotype 
was analysed in 2,087 patients taking escitalopram (2). It was found that 40% of the patients 
carrying preferentially CYP2C19*17 did not receive a therapeutic plasma dose during standard 
regimen and that 30% of patients carrying *2/*2 or *17/*17 genotypes switched medication within 
1 year as compared to 12% in the other genotype groups. He stressed the importance of pre-
emptive genotyping before starting escitalopram therapy. He presented data showing that the 
extent of rare genetic variants is very different between different pharmacogenes and that the 
overall contribution of rare variants to the variability in drug pharmacokinetics is 20-30%. 
Analyses of 204 pharmacogenes from 60,706 individuals (ExCAC) revealed 73,998 genetic 
variants of which 83% were novel and 98% were rare. In fact, 50 % of the variants were only seen 
in one individual. 
 
Dr. Scott Megill (USA) from Coriell Life Sciences, a commercial spin out of the Coriell Institute 
for Medical Research, providing pharmacogenetics services to hospital systems, clinics and 
individual practitioners in the U.S., Asia, Europe and South America, discussed what is needed for 
pharmacogenomics implementation from the perspectives of the population, health providers, 
patients and caregivers and then introduced GeneDoseLIVE, a physician and pharmacist tool for 
pharmacogenomic decision support. He emphasized that decision support tools can dramatically 
reduce the time required to produce individualized medication recommendations and serve as key 
educators for physicians in the proper use of genetic testing. Prof. Guilherme Suarez-Kurtz 
(BRA) discussed the impact of population diversity on the conceptual development and clinical 
implementation of pharmacogenetics. Data from Brazilians and Mexicans were used to highlight 
the diversity and complex admixture pattern of Latin American populations, in which the 
individual proportions of Native, European and African ancestry vary widely and, most 
importantly, in a continuous pattern, that is not captured by race/color/ethnic categorization, and 
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must be recognized in the design, interpretation and reporting of pharmacogenomic trials. Dr. 
Robin Everts (USA), from Agena Bioscience, showed data from a new copy number variation 
panel that allows a better overview of the CYP2D6 gene. The panel detects variations in 5 different 
sites throughout the CYP2D6 gene and could therefore detect samples containing hybrids such as 
*13 and *36.  The data showed that 5% of the samples tested contained a CYP2D6-CYP2D7 (*68) 
or CYP2D7-CYP2D6 (*13) hybrid allele that could potentially alter the phenotype. Due to the 
multiplexing of the assays in a single well, high throughput screening of many samples at the same 
time is possible and obsoletes the use of different techniques to test for these hybrid alleles. Prof. 
Adrian LLerena (ESP) Americans/Hispanics (588 million of people) that are product of Post-
Columbian admixture between the autochthonous Amerindians, Europeans, and African slaves 
and their descendants. This study is aimed at characterize the frequencies of CYP2D6, CYP2C9 or 
CYP2C19 alleles, as well as genotype-predicted poor or ultrarapid metabolizer phenotypes (gPMs 
or gUMs), in different populations from Latino and IberoAmerica, in a total of 6,060 individuals. 
A high interethnic variability has been described in several of CYP2D6, CYP2C9 and CYP2C19 
alleles, as well as CYP2D6 or CYP2C19 gPMs and gUMs. 
 
Dominique Dewolf (BE), affiliated to Life Technologies, opened this session presenting 
pioneering pharmacogenomic assays and technologies that may serve as pre-emptive 
pharmacogenomics strategies. Dr. Jari Forsström (FIN), an expert in health informatics at 
Åbomics, shared his experience towards the implementation of pre-emptive pharmacogenetic 
screening and reporting in the clinic. Opportunities and challenges were presented, considering the 
paradigm of the establishment of the Atuline Virtual Hospital. Dr. Daniella Steinberger (GER), 
CEO of bio.logis, acknowledged the current status of implementing genetic information for 
clinical use, reviewing the clinico-genomic tools and databases available. She introduced the 
Genetic Information Management Suite (GIMS) of bio.logis, an IT-based solution for the efficient 
management of genetic information and notably, after raising the question on what is still missing, 
Dr. Steinberger introduced the term “clinical interpretome” as the means to pave the way towards 
an actionable pharmacogenomics analysis. Dr. Theodora Katsilla (GR), affiliated to the 
University of Patras, emphasized on decision- and sense-making in genomic medicine and 
presented the potential of a human – artificial intelligence synergy to avoid biases. 
 
Prof. Sir Munir Pirmohamed (UK) underlined that despite recent Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guidelines demonstrating the economic benefit of pre-
emptive genotyping of both HLA-A*31:01 and HLA-B*15:02 for carbamazepine therapy (CBZ), 
regulatory efforts lag behind and no change in the summary of product characteristics (SmPC) for 
CBZ is foreseen. Prof. Markus Paulmichl (AT) followed with an underpinning message relevant 
to all stakeholders within the field of PGx - the genotyping results need to be right! The complexity 
of the CYP2D6 gene and surrounding locus was used to demonstrate how easy genotyping errors 
can be made. He highlighted the current EMA initiative to make the requirements related to the 
choice of appropriate genomic methodologies transparent, presented in the form of a guideline 
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entitled "Good Pharmacogenomic Practice" (see http://www.ema.europa.eu). Prof Mario 
Pazzagli (IT) rounded out the session with an overview on the aims and activities of the joint 
EFLM-ESPT (EFLM, European Federation of Clinical Chemistry and Laboratory Medicine) 
working group named "Personalized Laboratory Medicine", the main goal of which is to develop 
documents and disseminate knowledge on the implementation in the clinical laboratory of the 
personalized laboratory medicine approach in European countries. 
The symposium was concluded with a discussion session, started by a presentation of Prof Ron 
van Schaik on the European Pharmacogenetic Implementation Consortium (Eu-PIC, www.eu-
pic.net), which consists of 106 participants in 38 institutes in 19 (mostly) European countries, 
involving The Netherlands, Austria, Belgium, Denmark, Finland, France, Germany, Greece, 
Hungary, Italy, Luxemburg, Lithuania, Portugal, Serbia, Slovenia, Sweden, Switzerland, Turkey 
and the United Kingdom. A collaboration with the US Pharmacogenomics Research Network 
(PGRN) was recently established. The need for harmonization and exchange of experiences is the 
basis of this network, which focusses on clinical laboratories performing PGx analysis for 
diagnostics. The network has decided to collaborate with ESPT, and is now joining the Clinical 
Implementation Division of ESPT. Eu-PIC/ESPT are now involved in setting up PGx in Lithuania, 
Turkey, Serbia and Italy. After this, the new call in HORIZON2020 was addressed, and 
opportunities to submit a proposal there, discussed, especially project SC1-BHC-25-2019: 
demonstration pilots for implementation of personalized medicine in health care. A discussion 
session followed with the panel Sir Munir Pirmohamed, Markus Paulmichl, Guilherme Suarez-
Kurz, Magnus Ingelman-Sundberg, Filippo Drago, Mario Pazzagli (EFLM) and Romano Danesi, 
addressing the barriers and potential solutions to move the implementation of PGx in Europe. 
Filippo Drago pointed out that lack of knowledge on physicians as well as lack of access to testing 
were barriers. Whereas on one hand the need for solid evidence prior to implementation was 
acknowledged by the panel, the example of clopidogrel and CYP2C19 was put forward to show 
that the phrase “sufficient evidence” could still be interpreted rather broad: whereas the FDA has 
put a boxed warning on CYP2C19 in the drug label of clopidogrel, the European Society for 
Cardiology in their guidelines still indicated that “insufficient prospective evidence” was there to 
recommend genetic testing of CYP2C19. The apparent position of genetic testing was discussed, 
and whether this special position was justified. PGx is a lab test, and not a new drug. In that respect, 
it was remarked that the requested randomized controlled trials fitted better with the introduction 
of a new drug, than the implementation of a new laboratory test. The difference in uptake of the 
DPYD genotyping for capecitabine was highlighted: whereas in The Netherlands, this test is now 
commonly used before starting therapy, the European Society for Medical Oncology (ESMO) does 
not recommend this test (yet), Prof Romano Danesi remarked. Conclusion was that still more 
knowledge and implementation projects were needed to drive the implementation of PGx. 
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